Neucore Bio Inc. has received a $350,000 STTR phase I grant from the National Center for Advancing Translational Sciences (NCATS) at the U.S. National Institutes of Health (NIH) to evaluate the company’s targeted exosome platform to deliver an RNA-based therapy to treat Charcot-Marie-Tooth disease type 1a (CMT1A).
Researchers have identified a potential therapeutic target for muscular dystrophies, a group of genetic disorders characterized by progressive muscle weakness and degeneration. The study reveals that inhibiting the microRNA (miRNA) known as miRNA-33 can significantly improve muscle regeneration and ameliorate the dystrophic phenotype in animal models.
Arrowhead Pharmaceuticals Inc. has announced a global licensing and collaboration agreement with Novartis AG for ARO-SNCA, Arrowhead’s preclinical stage siRNA therapy for the treatment of synucleinopathies such as Parkinson’s disease, and for additional targets.
Shanghai Huilun Pharmaceutical Co. Ltd. has described sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers reported to be useful for the treatment of pain, multiple sclerosis, Charcot-Marie-tooth disease and arrhythmia.
Researchers from Cardiff University have discovered a new class of highly potent and selective inhibitors targeting the LIM domain kinases (LIMKs), a family of enzymes that play a critical role in regulating actin filament turnover. This turnover is involved in the cytoskeletal remodeling, proliferation and migration.
Researchers at Zhengzhou University and two of its affiliated hospitals explored in a mouse model whether brozopine might mitigate ischemia-induced vascular dementia.
Luye Innomind Pharma Shijiazhuang Co. Ltd. has divulged salts of 5-HT2A receptor inverse agonists with improved stability reported to be useful for the treatment of bipolar disorder, depression, Parkinson’s disease, Huntington’s disease, Alzheimer’s disease, sleep disorders, anxiety disorders and schizophrenia.
Palobiofarma SL has announced the successful completion of an industrial research project investigating dual antagonist compounds targeting adenosine A2A and histamine H3 receptors for the treatment of Parkinson’s disease.
Two independent studies have linked neuronal injury, inside or outside the brain, to cancer progression and offer new biomarkers and strategies for prevention. While cerebral cancer cells damage axons and drive tumor development, in other types of cancer affecting other organs, nerve disruption caused by tumor proximity triggers inflammation and a suppressive environment that may also be associated with immunotherapy resistance.
Chengdu Kanghong Pharmaceutical Co. Ltd. has described orexin OX2 receptor (OX2R; HCRTR2) antagonists reported to be useful for the treatment of secondary insomnia and major depression.
RSS
